Evidence map›Paper›PMID 29895660›Full record

ArticleBlood2018

Normalizing hepcidin predicts

Matthew M Heeney, Dongjing Guo, Luigia De Falco, Dean R Campagna, Gordana Olbina, Paige P-C Kao, Klaus Schmitz-Abe, Fedik Rahimov, Patrick Gutschow, Keith Westerman and 9 more

Erratum issuedOpen access · bronzeAbstract readLetter
In one paragraph

Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Recent Advances in Research on Iron Metabolism, Ferritin, and Hepcidin.International journal of molecular sciences · 2026
    Pooled it
  2. Review
  3. Review
  4. Iron Deficiency Anemia.Advances in experimental medicine and biology · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Hepcidin and Iron in Health and Disease.Annual review of medicine · 2023
    Review
  9. Article
  10. Hepcidin as a Potential Biomarker for the Diagnosis of Anemia.Turkish journal of pharmaceutical sciences · 2022
    Article
  11. Transferrin Saturation/Hepcidin Ratio DiscriminatesInternational journal of molecular sciences · 2022
    Article
  12. Article
  13. Roxadustat Does Not Affect Platelet Production, Activation, and Thrombosis Formation.Arteriosclerosis, thrombosis, and vascular biology · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Hepcidin and Anemia: A Tight Relationship.Frontiers in physiology · 2019
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 3 countries.

Matthew M HeeneyDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA.ORCID 0000-0002-1104-6843
Dongjing GuoDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA.
Luigia De FalcoDepartment of Molecular Medicine and Medical Biotechnologies, Federico II University Medical School, Naples, Italy.
Dean R CampagnaDepartment of Pathology, Boston Children's Hospital, Boston, MA.
Gordana OlbinaIntrinsic LifeSciences, La Jolla, CA.
Paige P-C KaoDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA.
Klaus Schmitz-AbeDivision of Newborn Medicine, and.
Fedik RahimovDivision of Genetics and Genomics, Department of Medicine, Boston Children's Hospital, Boston, MA.
Patrick GutschowIntrinsic LifeSciences, La Jolla, CA.
Keith WestermanIntrinsic LifeSciences, La Jolla, CA.
Vaughn OstlandIntrinsic LifeSciences, La Jolla, CA.
Tracy JacksonDivision of Pediatric Hematology-Oncology, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada; and.
Robert J KlaassenDivision of Pediatric Hematology-Oncology, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada; and.
Kyriacos MarkianosDepartment of Pathology, Boston Children's Hospital, Boston, MA.
Karin E FinbergDepartment of Pathology, Yale University, New Haven, CT.
Achille IolasconDepartment of Molecular Medicine and Medical Biotechnologies, Federico II University Medical School, Naples, Italy.
Mark WestermanIntrinsic LifeSciences, La Jolla, CA.
Wendy B LondonDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA.
Mark D FlemingDepartment of Pathology, Boston Children's Hospital, Boston, MA.ORCID 0000-0003-0948-4024
Boston Children's Hospital · USIntrinsic LifeSciences (United States) · USChildren's Hospital of Eastern Ontario · CAFederico II University Hospital · ITHarvard University · USYale University · US

Funding

supplemental funding for Phase 2B NIDDK grantR44DK083843 · NIDDK · INTRINSIC LIFESCIENCES, LLC · PI OSTLAND, VAUGHN E · 2011 to 2016
$5.7M
Clinical Hematology Research Career Development Program (K12)K12HL087164 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI CANTOR, ALAN B. · 2006 to 2016
$3.9M
NHLBI NIH HHS K12 HL087164NIDDK NIH HHS R44 DK083843
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MutationAdultAnemia, Iron-DeficiencyHepcidinsHumansIronMembrane ProteinsMiddle AgedPrognosisSerine EndopeptidasesHepcidinsIronMembrane ProteinsSerine EndopeptidasesTMPRSS6 protein, human

Identifiers

PMID29895660
PMCPMC6071554
OpenAlexW2808201717

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.